Vismodegib for locally advanced basal cell carcinoma: Descriptive analysis of a case series and comparison to the literature

Journal of Drugs in Dermatology

Volumn 14, Issue 9, 2015, Pages 956-962

  Viscusi, Kathleen Sikora ^a   Hanke, C William ^a  

^a Laser and Skin Surgery Center of Indiana   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ERIVEDGE TM; GDS 0449; VISMODEGIB; ANILIDE; ANTINEOPLASTIC AGENT; PYRIDINE DERIVATIVE;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ARTICLE; BASAL CELL CARCINOMA; BLEEDING; CANCER CHEMOTHERAPY; CASE REPORT; CASE STUDY; CLINICAL ARTICLE; DEATH; DECREASED APPETITE; DESCRIPTIVE RESEARCH; DISEASE FREE SURVIVAL; DIZZINESS; DRUG EFFICACY; DRUG TOLERABILITY; DYSGEUSIA; FEMALE; FOLLOW UP; HAIR LOSS; HEADACHE; HUMAN; HUMAN TISSUE; LETHARGY; MALE; MUSCLE CRAMP; NAUSEA; NAUSEA AND VOMITING; RECURRENT DISEASE; SKIN BIOPSY; TREATMENT OUTCOME; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; TUMOR GROWTH; TUMOR VOLUME; VERY ELDERLY; CARCINOMA, BASAL CELL; CHEEK; COMPARATIVE STUDY; DISEASE COURSE; FACIAL NEOPLASMS; FOREHEAD; MIDDLE AGED; NOSE; PATHOLOGY; SCALP; SKIN NEOPLASMS; THORAX;

ADULT; AGED; AGED, 80 AND OVER; ANILIDES; ANTINEOPLASTIC AGENTS; CARCINOMA, BASAL CELL; CHEEK; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FACIAL NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; FOREHEAD; HUMANS; MALE; MIDDLE AGED; NOSE; PYRIDINES; SCALP; SKIN NEOPLASMS; THORAX; TREATMENT OUTCOME; TUMOR BURDEN;

EID: 84976308206     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Rubin AI, Chen EH, Ratner D. Basal-cell carcinoma. N Engl J Med. 2005;353:2262–9.
2. Caro I, Low JA. The role of the Hedgehog signaling pathway in the development of basal cell carcinoma and opportunities for treatment. Clin Cancer Res. 2010;16:3335-9.
3. Sekulic A, Migden MR, Oro AE, Dirix L, Lewis KD, Hainsworth JD, et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med. 2012;366:2171-9.
4. Basset-Seguin N, Sharpe HJ, Sauvage FJ. Efficacy of Hedgehog Pathway Inhibitors in Basal Cell Carcinoma. Mol Cancer Ther. 2015;1-9.
5. Yin VT, Sniegowski M, Esmaeli B. To the editor: Indications and limitations of vismodegib for basal cell carcinoma. JAMA Ophthalmol. 2014;132(7):905-906.
6. Gill HS, Moscato EE, Silkiss RZ. In reply: Indications and limitations of vismodegib for basal cell carcinoma. JAMA Ophthalmol. 2014;132(7):906.
7. Chang AL, Solomon JA, Hainsworth JD, et al. Expanded access study of patients with advanced basal cell carcinoma treated with the Hedgehog pathway inhibitor, vismodegib. J AmAcad Dermatol. 2014;70(1):60-69.
8. Saintes C, Saint-Jean M, Brocard A, et al. Development of squamous cell carcinoma into basal cell carcinoma under treatment with vismodegib. J Eur Acad Dermatol. 2014; Jul 1. [Epub ahead of print]
9. Zhu GA, Sundram U, Chang AL. Two different scenerios of squamous cell carcinoma within advanced basal cell carcinomas: cases illustrating the importance of serial biopsy during vismodegib usage. JAMA Dermatol. 2014; 150: 970–973.
10. Iarrobino A, Messina JL, Kudchadkar R, et al. Emergence of a squamous cell carcinoma phenotype following treatment of metastatic basal cell carcinoma with vismodegib. J Am Acad Dermatol. 2013;69(1):e33-e34.
11. Aasi S, Silkiss R, Tang JY, et al. New onset of keratoacanthomas after vismodegib treatment for locally advanced basal cell carcinomas: a report of 2 cases. JAMA Dermatol. 2013;149(2):242-243.
12. Orouji A, Goerdt S, Utikal J, et al. Multiple highly and moderately differentiated squamous cell carcinomas of the skin during vismodegib treatment of inoperable basal cell carcinoma. Br J Dermatol. 2014;171:431–3
13. Tang JY, Mackay-Wiggan JM, Aszterbaum M, et al. Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome. N Engl J Med. 2012;366:2180-8.
14. Ally MS, Aasi S, Wysong A, et al. An investigator-initiated open-label clinical trial of vismodegib as a neoadjuvant to surgery for high-risk basal cell carcinoma. Journal Am Acad Dermatol. 2014;71(5):904-911.
15. Grob JJ, Kunstfeld R, Dreno B, et al. Vismodegib a hedgehog pathway inhibitor (HPI) in advanced basal cell carcinoma (aBCC); Stevie study interim analysis in 300 patients. J Clin Oncol. 31, 2013 (suppl; abstr 9036).
16. Erdem GU, Sendur MAN, Ozdemir NY, et al. A comprehensive review of the role of the hedgehog pathway and vismodegib in the management of basal cell carcinoma. Curr Med Res Opin. 2015;31(4):743-756.
17. Gill HS, Moscato EE, Chang ALS, et al. Vismodegib for periocular and orbital basal cell carcinoma. JAMA Ophthalmol. 2013;131(12):1591-1594.
18. LoRusso PM, Rudin CM, Reddy JC, et al. Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors. Clin Cancer Res. 2011; 17(8): 2502-2511
19. Von Hoff DD, LoRusso PM, Rudin CM, et al. Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N Engl J Med. 2009; 361(12): 1164-72
20. Graham RA, Lum BL, Cheeti S, et al. Pharmacokinetics of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with locally advanced or metastatic solid tumors: the role of alpha-1-acid glycoprotein binding. Clin Cancer Res. 2011; 17(8):2512-20
21. Rudin CM. Vismodegib. Clin Cancer Res. 2012;18:3218–22
22. Wolfe CM, Green WH, Cognetta AB Jr, et al. Basal cell carcinoma rebound after cessation of vismodegib in a nevoid basal cell carcinoma syndrome patient. Dermatol Surg. 2012;38:1863-6.
23. Chang ALS, Oro AE. Initial assessment of tumor re-growth after vismodegib in advanced basal cell carcinoma. Arch Dermatol. 2012;148:1324–1325.
24. Sekulic A, Hainsworth JD, Lewis KD, et al. Vismodegib for advanced basal cell carcinoma: duration of response after vismodegib discontinuation and response to vismodegib retreatment upon disease progression. J Clin Oncol. 2014;32(Suppl):abstract 908.
25. Sekulic A, Migden MR, Basset-Seguin N, Garbe C, Gesierich A, Lao CD, et al. Long term safety and Efficacy of vismodegib in patients with advanced basal cell carcinoma (aBCC): 18 months update of the pivotal ERIVANCE BCC study. J Clin Oncol. 2013;31:15s(suppl; abstr 9037).